The Colorado legislature is currently considering a bill that would specifically exempt orphan drugs from any pricing limits that the state may implement.
This move comes amid broader discussions on pharmaceutical pricing and access, particularly for drugs that treat rare diseases.
The implications of this legislation could significantly affect the market dynamics for orphan drugs, influencing both pricing strategies and patient access.